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baseline showed improvement in severity of regurgitation. Patients with moderate MR
or above demonstrated the greatest improvement.
TCT-780
Clinical Outcomes of Asian Patients with Low to Intermediate Risk Undergoing
Transcatheter Aortic Valve Implantation
Sung-Han Yoon1, Jung-Min Ahn1, Michael Kang-Yin Lee2, Edgar L. Tay3,
Young-Hak Kim1, Cheol Whan Lee1, Dong Hyun Yang1, Joon-Won Kang1,
Jong-Young Lee1, Hyo In Choi1, Jae Hyung Roh1, Pil Hyung Lee1, Mineok Chang1,
Hyun Woo Park1, Soo-Jin Kang1, Duk-Woo Park4, Seung-Whan Lee1,
Jong-Min Song1, Seong-Wook Park1, Seung-Jung Park1
1Asan Medical Center, Seoul, Korea, Republic of, 2Queen Elizabeth Hospital,
Kowloon, China, 3National University Heart Centre, Singapore, Singapore, 4Asan
Medical Center, Seoul, Korea, Seoul, Korea, Republic of
Background: Transcatheter aortic valve implantation (TAVI) is an established
treatment alternative to surgical aortic valve replacement in high-risk and inoperable
patients and outcomes among patients with intermediate risk remain to be determined.
The aim of this study was to assess clinical outcomes among Asian patients with low
to intermediate risk undergoing TAVI.
Methods: Data from Asian TAVI multicenter registry were pooled and analyzed. In
total, 185 patients with severe symptomatic aortic stenosis undergoing TAVI were
categorized according to the Society of Thoracic Surgeons (STS) score into low (STS
< 3%; N ¼ 82, 44.3%), intermediate (STS  3% and  8%; N ¼ 77, 41.6%), and
high risk (STS > 8%; N ¼ 26, 14.1%) groups.
Results: Signiﬁcant differences were found between the groups (low risk vs. interme-
diate risk vs. high risk) for age (75.6 5.5 vs. 80.5 5.2 vs. 80.1 6.7, p< 0.001), body
mass index (25. 5  3.1 vs. 23.6  3.7 vs. 23.2  3.1, p ¼ 0.001), diabetes (21.3% vs.
46.7% vs. 68.4%, p < 0.001), previous coronary artery bypass surgery (1.3% vs. 6.7%
vs. 21.1%, p ¼ 0.004), and peripheral artery disease (4.0% vs. 8.3% vs. 42.1%, p <
0.001). No differences were observed with regards to major vascular complication,
postoperative aortic regurgitation  moderate, new permanent pacemaker, device suc-
cess and all-cause mortality at 30 days, however signiﬁcant difference was found for all-
cause mortality at 1-year (2.5% vs. 11.3% vs. 17.9%, p ¼ 0.043).
Conclusions: Compared with patients at high risk, patients with low or intermediate
risk have favorable clinical outcomes after TAVI in the Asian population.B228 JACC Vol 64/11/Suppl B j SepTCT-781
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Background: Vascular and bleeding complications are common following trans-
catheter aortic valve replacement (TAVR). The impact of the expandable sheath (e-
sheath) for trans-femoral Edwards aortic valve replacement is unclear. Our objective
was to compare the incidence of procedural complication when using 18Fr ﬁxed size
sheath vs. 16 to 18Fr e-sheath during TAVR.
Methods: We enrolled 90 consecutive patients who underwent TAVR with
Edwards valve at our center. Since June 2011 e-sheath has been routinely
employed to obtain femoral access. Prostar System for vascular hemostasis, and
intraprocedural heparin monitored by activated clotting time were used in all
cases. We compared baseline and procedural outcomes according to the use of
e-sheath. Vascular and bleeding complications were deﬁned using the VARC-2
deﬁnitions.
Results: Patients receiving e-sheath (n¼54, 60%) matched for age, sex, body mass
index, rate of peripheral artery disease, diabetes, and chronic kidney disease compared
to those treated with ﬁxed size sheath. E-sheath use was associated with reductions in
major or life-threatening bleeding (5.6% vs. 39%, p< 0.001) and minor vascular
complication (24% vs. 39%, p¼0.31), while major vascular complication (7.4% vs.
5.6%, p¼0.73), and procedural mortality (0.0% vs 2.7%, p¼0.21) resulted not
signiﬁcantly different (Figure 1).Conclusions: The use of e-sheath is associated with substantial reductions in bleeding
and minor vascular bleeding, during trans-femoral TAVR, while an advantage in term
of major vascular complication was not readily apparent.
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Background: Serious vascular complications have been reported to occur in 6% of
the transfemoral TAVI patients. The aim was to report access site related complica-
tions using Single (SP) versus Double (DP) Prostar XL for closure of 18F femoral
arterial access in TAVI.
Methods: 134 patients included in our prospective TAVI database at Karolinska
University Hospital (Nov 2012- Feb 2014), transfemoral-TAVI was performed in
126 patients using 18F sheath. The ﬁrst 63 consecutive patients were treated with
SP and the last 63 patients with DP closure. Primary endpoint was deﬁned as ac-
cess-site related vascular complication (femoral hematoma >4 cm in diameter,
external femoral bleeding, retroperitoneal hematoma or blood transfusion within
1 week after the procedure). Secondary endpoint was deﬁned as post-procedure
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